DebasishSundiMD

PubMed

• Roles of Androgen Receptor Signaling in Urothelial Carcinoma.
  Diaz, D., Gupta, S., Carson, W., Sundi, D., Collier, K., Yang, Y., Pohar, K., Singer, E., Clinton, S., Li, Z., Messing, E.> ;Cancers. 2024 Feb 10
• Editorial Comment.
  Sundi, D.> ;The Journal of Urology. 2024 Apr 1
• A Comprehensive Review of Immunotherapy Clinical Trials for Metastatic Urothelial Carcinoma: Immune Checkpoint Inhibitors Alone or in Combination, Novel Antibodies, Ce...
  Carrillo, A., Mortazavi, A., Patel, D., Mateen, R., Qaddour, N., Verschraegen, C., Yang, Y., Li, Z., Sundi, D., Collier, K.> ;Cancers. 2024 Jan 12
• Melanoma Antigen Family A (MAGE A) as Promising Biomarkers and Therapeutic Targets in Bladder Cancer.
  Verma, S., Swain, D., Kushwaha, P., Brahmbhatt, S., Gupta, K., Gupta, S., Sundi, D.> ;Cancers. 2024 Jan 5
• PrECOG PrE0807: A Phase 1b Feasibility Trial of Neoadjuvant Nivolumab Without and with Lirilumab in Patients with Muscle-invasive Bladder Cancer Ineligible for or Refu...
  Chu, X., Cole, S., Gartrell, B., Woo, B., Li-Ning-Tapia, E., Grivas, P., Koshkin, V., Jain, R., Dreicer, R., Cetnar, J., Sundi, D., Galsky, M., Hahn, N., Carducci, M.> ;European Urology Oncology. 2023 Dec 27
• BTK inhibition potentiates anti-PD-L1 treatment in murine melanoma: potential role for MDSC modulation in immunotherapy.
  Steven H Sun, Colin D Angell, Himanshu Savardekar, Debasish Sundi, David Abood, Brooke Benner, Mallory J DiVincenzo, Megan Duggan, Fouad Choueiry, Thomas Mace, Prashan...> ;Cancer Immunology, Immunotherapy. 2023 Nov 1
• Development and Multicenter Case-Control Validation of Urinary Comprehensive Genomic Profiling for Urothelial Carcinoma Diagnosis, Surveillance, and Risk-Prediction.
  Keyan Salari, Debasish Sundi, Jason J Lee, Shulin Wu, Chin-Lee Wu, Gabrielle DiFiore, Q Robert Yan, Andrew Pienkny, Chi K Lee, Daniel Oberlin, Greg Barme, Joel Piser, ...> ;Clinical Cancer Research. 2023 Sep 15
• 1 citations
  Conditional Reprogramming Modeling of Bladder Cancer for Clinical Translation.
  Danyal Daneshdoust, Ming Yin, Mingjue Luo, Debasish Sundi, Yongjun Dang, Cheryl Lee, Jenny Li, Xuefeng Liu> ;Cells. 2023 Jun 24
• Heterogeneity of BCG unresponsive bladder cancer clinical trials limits patients' access to novel therapeutics.
  Michael Chandra, Roger Li, Anil Parwani, William E Carson 3rd, Kamal Pohar, Debasish Sundi> ;Urologic Oncology. 2023 Sep 1
• Salvage lenvatinib/everolimus combination therapy after immune checkpoint inhibitor and VEGFR tyrosine kinase inhibitor for metastatic renal cell carcinoma.
  Christopher Kwok, Adam Khorasanchi, Sarah P Psutka, Megan Hinkley, Shawn Dason, Debasish Sundi, Yuanquan Yang, Yajing Yang, Claire Verschraegen, Evan E Gross, Delaney ...> ;Frontiers in Oncology. 2023 Jan 1
• Editorial Comment.
  Shagnik Ray, Debasish Sundi> ;The Journal of Urology. 2022 Sep 1
• 11 citations
  Sex-biased adaptive immune regulation in cancer development and therapy.
  Johanna M Schafer, Tong Xiao, Katharine Collier, Yuzhou Chang, Hany Abdel-Hafiz, Chelsea Bolyard, Dongjun Chung, Yuanquan Yang, Debasish Sundi, Qin Ma, Dan Theodorescu...> ;Iscience. 2022 Aug 19
• Editorial Comment.
  Johanna M Schafer, Debasish Sundi> ;The Journal of Urology. 2022 Oct 1
• 60 citations
  Androgen conspires with the CD8T cell exhaustion program and contributes to sex bias in cancer.
  Hyunwoo Kwon, Johanna M Schafer, No-Joon Song, Satoshi Kaneko, Anqi Li, Tong Xiao, Anjun Ma, Carter Allen, Komal Das, Lei Zhou, Brian Riesenberg, Yuzhou Chang, Payton ...> ;Science Immunology. 2022 Jul 1
• EDITORIAL COMMENT.
  Johanna Schafer, Debasish Sundi> ;Urology. 2022 Jul 1
• 10 citations
  Oncologic outcomes among Black and White men with grade group 4 or 5 (Gleason score 8-10) prostate cancer treated primarily by radical prostatectomy.
  Lamont Wilkins, Jeffrey J. Tosoian, Chad A. Reichard, Debasish Sundi, Weranja Ranasinghe, Ridwan Alam, Zeyad Schwen, Chandana A. Reddy, M.E. Allaf, John W. Davis, Bria...> ;Cancer. 2021 May 1
• Robotic Radical Cystectomy, Pelvic Lymph Node Dissection, and Intracorporeal Ileal Conduit Urinary Diversion
  Stephanie A. Stillings, Debasish Sundi> ;Journal of Visualized Experiments. 2021 Mar 10
• 4 citations
  Neoadjuvant chemotherapy in bladder cancer: Clinical benefit observed in prospective trials computed with restricted mean survival times.
  Zachary R. McCaw, Anobel Y. Odisho, Hemant Chaparala, Ming Yin, Jordan M. Cloyd, Robert S. Svatek, William E. Carson, Cheryl T. Lee, Debasish Sundi> ;Urologic Oncology. 2021 Jan 10
• Needle in a haystack: Robotic removal of a retroperitoneal wire.
  Max S. Yudovich, Daniel D. Evans, Kathleen Puttmann, James A. Payne, Nima Baradaran, Debasish Sundi> ;Urology Case Reports. 2021 Jan 1
• 11 citations
  Surgical management of high-risk, localized prostate cancer.
  Lamont Wilkins, Jeffrey J. Tosoian, Debasish Sundi, Ashley E. Ross, Dominic C. Grimberg, Eric A. Klein, Brian F. Chapin, Yaw A. Nyame> ;Nature Reviews. Urology. 2020 Nov 10
• 7 citations
  Downgrading from Biopsy Grade Group 4 Prostate Cancer in Patients Undergoing Radical Prostatectomy for High or Very High Risk Prostate Cancer.
  Weranja Ranasinghe, Chad A. Reichard, Yaw A. Nyame, Debasish Sundi, Jeffrey J. Tosoian, Lamont Wilkins, Ridwan Alam, Mary Achim, Xuemei Wang, Andrew J. Stephenson, Eri...> ;The Journal of Urology. 2020 Oct 1
• 25 citations
  Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guérin.
  Roger Li, Debasish Sundi, Jingsong Zhang, Young-Chul Kim, Richard Sylvester, Philippe E. Spiess, Michael A. Poch, Wade J. Sexton, Peter C. Black, James M. McKiernan, G...> ;European Urology. 2020 Sep 1
• 12 citations
  Does time from diagnosis to treatment of high- or very-high-risk prostate cancer affect outcome?
  Chad A. Reichard, Yaw A. Nyame, Debasish Sundi, Jeffrey J. Tosoian, Lamont Wilkins, Ridwan Alam, Mary Achim, Xuemei Wang, Andrew J. Stephenson, Eric A. Klein, Ashley E...> ;BJU International. 2019 Aug 1
• 4 citations
  Survival after radiotherapy vs. radical prostatectomy for unfavorable intermediate-risk prostate cancer.
  Nikhil Sebastian, Joseph P. McElroy, Douglas Martin, Debasish Sundi, Dayssy Alexandra Diaz> ;Urologic Oncology. 2019 May 18
• Editorial Comment.
  Debasish Sundi, Yaw A Nyame> ;The Journal of Urology. 2019 Aug 1
• Join now to see all